SAN DIEGO, April 29, 2010 /PRNewswire via COMTEX/ --NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today that it will host a meeting for investors and analysts at the St. Regis Hotel, 2 East 55th St., New York, NY, on Friday, May 7, 2010 from 7:00 to 10:30 a.m. ET.
The agenda will include a strategic update from management, surgeon and patient panel presentations, procedure-specific product demonstrations, and an audience Q&A with both management and surgeons.
NuVasive is honored to have the participation of the following leading spine surgeons:
- Dr. Christopher R. Brown, Duke University Medical Center
- Dr. Andrew Cappuccino, Buffalo Spine Surgery
- Dr. Eric Elowitz, Weill Cornell Medical College
- Dr. Jeffrey Goldstein, NYU Hospital for Joint Diseases
- Dr. James Hale, Eastern Orthopedic Associates
- Dr. W. Blake Rodgers, Spine Midwest, Inc.
- Dr. David Schwartz, Ortho Indy
- Dr. William Smith, Western Regional Center for Brain & Spine Surgery
Several members of NuVasive executive management will be in attendance including:
- Alex Lukianov, Chairman and Chief Executive Officer
- Keith Valentine, President and Chief Operating Officer
- Michael Lambert, Executive Vice President and Chief Financial Officer
- Patrick Miles, President of the Americas
A live webcast of the meeting will be available online from the investor relations page of the Company's corporate website at www.nuvasive.com. After the live webcast, the presentation will remain available on the website for 30 days.
NuVasive is a medical device company focused on the design, development, and marketing of products for the surgical treatment of spine disorders. The Company's product portfolio is focused primarily on the $5.1 billion U.S. spine implant market. Additionally, the Company has expanded into the $1.7 billion global biologics market, the $1.7 billion international market, and is developing products for the emerging motion preservation market.
NuVasive's principal product offering is based on its Maximum Access Surgery, or MAS(R) platform. The MAS platform combines four categories of products that collectively minimize soft tissue disruption during spine surgery with maximum visualization and safe, easy reproducibility for the surgeon: NeuroVision(R), a proprietary software-driven nerve avoidance system; MaXcess(R), a unique split-blade retractor system; a wide variety of specialized implants; and several biologic fusion enhancers. MAS significantly reduces surgery time and returns patients to activities of daily living much faster than conventional approaches. Having redefined spine surgery with the MAS platform's lateral approach, known as eXtreme Lateral Interbody Fusion, or XLIF(R), NuVasive has built an entire spine franchise. With over 55 products today spanning lumbar, thoracic and cervical applications, the Company will continue to expand and evolve its offering predicated on its R&D focus and dedication to outstanding service levels supported by a culture of Absolute Responsiveness(R).
NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to: the risk that NuVasive's revenue or earnings projections may turn out to be inaccurate because of the preliminary nature of the forecasts and the risk of further adjustment, or unanticipated difficulty in selling products or generating expected profitability; the uncertain process of seeking regulatory approval or clearance for NuVasive's products or devices, including risks that such process could be significantly delayed; the possibility that the FDA may require significant changes to NuVasive's products or clinical studies; the risk that products may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; the risk that additional clinical data may call into question the benefits of NuVasive's products to patients, hospitals and surgeons; and other risks and uncertainties more fully described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
Contact: Investors: Michael Lambert Patrick F. Williams EVP & Chief Financial Vice President, Finance & Investor Officer Relations NuVasive, Inc. NuVasive, Inc. 858-909-1998 858-638-5511 firstname.lastname@example.org email@example.com Media: Jason Rando The Ruth Group 646-536-7025 firstname.lastname@example.org
SOURCE NuVasive, Inc.